JP2024508762A5 - - Google Patents

Info

Publication number
JP2024508762A5
JP2024508762A5 JP2023549819A JP2023549819A JP2024508762A5 JP 2024508762 A5 JP2024508762 A5 JP 2024508762A5 JP 2023549819 A JP2023549819 A JP 2023549819A JP 2023549819 A JP2023549819 A JP 2023549819A JP 2024508762 A5 JP2024508762 A5 JP 2024508762A5
Authority
JP
Japan
Application number
JP2023549819A
Other languages
Japanese (ja)
Other versions
JP2024508762A (ja
JPWO2022178158A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/016840 external-priority patent/WO2022178158A1/en
Publication of JP2024508762A publication Critical patent/JP2024508762A/ja
Publication of JP2024508762A5 publication Critical patent/JP2024508762A5/ja
Publication of JPWO2022178158A5 publication Critical patent/JPWO2022178158A5/ja
Pending legal-status Critical Current

Links

JP2023549819A 2021-02-18 2022-02-17 抗tl1a抗体組成物及び肺における治療方法 Pending JP2024508762A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163150832P 2021-02-18 2021-02-18
US63/150,832 2021-02-18
US202163180896P 2021-04-28 2021-04-28
US63/180,896 2021-04-28
US202163226041P 2021-07-27 2021-07-27
US63/226,041 2021-07-27
US202163285785P 2021-12-03 2021-12-03
US63/285,785 2021-12-03
PCT/US2022/016840 WO2022178158A1 (en) 2021-02-18 2022-02-17 Anti-tl1a antibody compositions and methods of treatment in the lung

Publications (3)

Publication Number Publication Date
JP2024508762A JP2024508762A (ja) 2024-02-28
JP2024508762A5 true JP2024508762A5 (https=) 2025-02-26
JPWO2022178158A5 JPWO2022178158A5 (https=) 2025-02-26

Family

ID=82931034

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549819A Pending JP2024508762A (ja) 2021-02-18 2022-02-17 抗tl1a抗体組成物及び肺における治療方法

Country Status (10)

Country Link
US (1) US20240336691A1 (https=)
EP (1) EP4294443A4 (https=)
JP (1) JP2024508762A (https=)
KR (1) KR20230158494A (https=)
AU (1) AU2022221712A1 (https=)
BR (1) BR112023016574A2 (https=)
CA (1) CA3207818A1 (https=)
MX (1) MX2023009681A (https=)
TW (1) TW202302640A (https=)
WO (1) WO2022178158A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
JP2022533956A (ja) 2019-05-14 2022-07-27 プロメテウス バイオサイエンシーズ,インク. Tl1a患者を選択する方法、システム、およびデバイス
KR20220103721A (ko) 2019-10-24 2022-07-22 프로메테우스 바이오사이언시즈, 인크. Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도
EP4665394A2 (en) * 2023-02-17 2025-12-24 Prometheus Biosciences, Inc. Anti-tl1a antibody compositions and methods of treatment in the kidney
EP4665395A1 (en) * 2023-02-17 2025-12-24 Prometheus Biosciences, Inc. Anti-tl1a antibody compositions and methods of treatment in the liver
AU2024222357A1 (en) * 2023-02-17 2025-08-28 Cedars-Sinai Medical Center Anti-tl1a antibody compositions and methods of treating skin
WO2024186859A2 (en) * 2023-03-09 2024-09-12 Prometheus Biosciences, Inc. Anti-tl1a antibody compositions and methods of treatment for sarcoidosis
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法
US12473370B2 (en) 2023-10-03 2025-11-18 Absci Corporation TL1A associated antibody compositions and methods of use
TW202545995A (zh) 2024-01-26 2025-12-01 大陸商明濟生物製藥(北京)有限公司 能夠與tl1a特異性結合之抗體及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080233119A2 (en) * 2003-08-20 2008-09-25 University Of Miami Compositions and methods for treating inflammatory lung disease
WO2009114110A1 (en) * 2008-03-08 2009-09-17 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
JO3375B1 (ar) * 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
EA201591153A1 (ru) * 2013-01-02 2016-01-29 Гленмарк Фармасьютикалс С.А. Антитела, связывающиеся с tl1a, и их применение
MX388027B (es) * 2013-11-13 2025-03-19 Pfizer Anticuerpos específicos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos.
TWI703158B (zh) * 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
MY191324A (en) * 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
US10626180B2 (en) * 2017-04-20 2020-04-21 Cedars-Sinai Medical Center Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease
JP7332627B2 (ja) * 2018-04-25 2023-08-23 プロメテウス バイオサイエンシーズ,インク. 最適化された抗tl1a抗体
JP2022533956A (ja) * 2019-05-14 2022-07-27 プロメテウス バイオサイエンシーズ,インク. Tl1a患者を選択する方法、システム、およびデバイス
KR20220103721A (ko) * 2019-10-24 2022-07-22 프로메테우스 바이오사이언시즈, 인크. Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도

Similar Documents

Publication Publication Date Title
JP2024508762A5 (https=)
BR202022009269U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13174U (https=)
BY13161U (https=)
BY13149U (https=)
BY13145U (https=)
CN307048898S (https=)
CN307048355S (https=)
CN307047481S (https=)
CN307047466S (https=)
BY13144U (https=)
CN307047094S (https=)
CN307046976S (https=)
CN307046465S (https=)
BY13143U (https=)
CN307046295S (https=)
CN307045003S (https=)
CN307044922S (https=)
CN307044413S (https=)
CN307044385S (https=)
BY13142U (https=)
BY23963C1 (https=)
BY13176U (https=)